Global Pulmonary Arterial Hypertension Therapeutics Market Trends (2014-2024)

1
OpportunityAnalyzer Pulmonary Arterial
Hypertension - Opportunity Analysis and Forecast
to 2024
MarketIntelReports newly published a research
report on Global Pulmonary Arterial Hypertension
Therapeutics Market with covering detailed
analysis on market segmentation, global notable
vendors, geographical outlook, price financial
updates, segment application approach and
future forecasts.
Published on 01January, 2016 Number of pages
182 Single User Price 9495
2
Summary of ReportMarketIntelReports estimates
the 2014 sales for pulmonary arterial
hypertension (PAH) at approximately 3.45 billion
across the 7MM covered in this report, which
include the US, 5EU and Japan. The market will
grow moderately at a CAGR of 3.20 during the
10-year forecast period, generating sales of
approximately 4.75 billion at the end of 2024.
The US market is expected to grow the fastest of
the three regions, recording a CAGR of 3.70 and
generating around 75 of global sales in 2024.
The major drivers for this growth across the 7MM
will be the launch of Actelions Uptravi and the
increased use of double and triple combination
therapy.
3

• Key Questions Answered in Report
• The level of unmet needs in the PAH market is
  significantly high. Will the pipeline drugs
  fulfil these unmet needs of the market? Key
  Opinion Leaders (KOLs) interviewed by
  MarketIntelReports provide insights and highlight
  opportunities for drug developers.
• The 10-year forecast period will mark the launch
  of two late-stage pipeline drugs and the patent
  expirations of seven marketed drugs. How will the
  market be impacted? Which of the marketed and
  pipeline drugs will have the highest peak sales
  at the highest CAGR, and why?
• Is combination therapy the new standard-of-care
  in the PAH market? How will reimbursement affect
  the adoption of combination therapy in the
  different markets?

Click Here To Check Complete Report
4

• Key Findings of Report
• The major drivers for growth across the 7MM in
  the PAH market during the forecast period will be
  the launch of the first-in-class prostacyclin
  receptor agonist, Uptravi marketed by Actelion
  and the increased use of combination therapy.
• KOLs interviewed by Marketintelreports opined
  that Uptravi has a promising future as a
  second-line therapy in the PAH market, and has
  the potential to displace oral treprostinils
  market position.
• The highest revenue generators in the 7MM market
  at the end of 2024 will be Actelions Veletri,
  Opsumit and Uptravi and Bayers Adempas.
• In other interviews, KOLs highlighted that the
  greatest unmet need in the PAH disease space is
  the need to develop novel drugs with curative or
  disease-stabilizing properties.
• Low disease awareness, declining population in
  the 5EU and Japan, high cost of drugs and patent
  expirations of branded drugs are the major
  barriers for growth in the PAH market during the
  forecast period.

Download Sample Brochure
5
Key questions answered in this report  What
will the market size be in 2020 and what will the
growth rate be? What are the key market
trends? What is driving this market? What are
the challenges to market growth? Who are the
key vendors in this market space? What are the
market opportunities and threats faced by the key
vendors? What are the strengths and weaknesses
of the key vendors? You can request one free
hour of our analysts time when you purchase this
market report. Details are provided within the
report.
Make an Inquiry Before Buying
6
OpportunityAnalyzer Pulmonary Arterial
Hypertension - Opportunity Analysis and Forecast
to 2024
A detailed qualitative analysis of the factors
responsible for driving and restraining growth of
the Pulmonary Arterial Hypertension - Market
Market Shares, Strategies, and Forecasts,
Worldwide, 2016 to 2022 and future opportunities
are provided in the report.
Contact 1-302-684-6088 sales_at_marketintelreports.c
om www.marketintelreports.com
Click Here To Order Pulmonary Arterial
Hypertension Therapeutics Market Analysis